Specifically, psoriasin/S100A7 has been associated with the pre-invasive DCIS phenotype [2], augmentation of several characteristics of malignancy in vitro and in vivo [4,6] and with poor outcome in invasive estrogen receptor-negative tumors [3,5]. Here, ESR1 is linked to ductal breast carcinoma in situ.